Fluticasone extended-release - Flexion Therapeutics

Next Previous
Drug Profile

Fluticasone extended-release - Flexion Therapeutics

Alternative Names: FX 101 - Flexion Therapeutics

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flexion Therapeutics
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Musculoskeletal pain

Most Recent Events

  • 08 Mar 2018 Flexion Therapeutics has patents pending for Fluticasone extended-release in USA and other countries worldwide
  • 09 Aug 2017 Chemical structure information added
  • 10 Jul 2017 Preclinical trials in Musculoskeletal pain in USA (unspecified route) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top